• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

明天的治疗药物监测。

Therapeutic drug monitoring for tomorrow.

机构信息

Karolinska University Laboratory, Department of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden.

出版信息

Eur J Clin Pharmacol. 2013 May;69 Suppl 1:25-32. doi: 10.1007/s00228-013-1504-x. Epub 2013 May 3.

DOI:10.1007/s00228-013-1504-x
PMID:23640185
Abstract

Therapeutic drug monitoring (TDM) represents an early approach to personalised medicine. It helps the clinician to individualise drug treatment and guide dosage to reach systemic drug concentrations associated with therapeutic efficacy and/or to reduce the risk of concentration-dependent adverse effects. Well into the fifth decade of TDM as a service to healthcare, this concept is still expanding, and new areas for clinical implementation continue to emerge. The aim of this overview is to discuss promising new therapeutic areas in future TDM services, how to improve the clinical interpretation of single drug measurements and how recent technology development opens the doors to research and new applications.

摘要

治疗药物监测(therapeutic drug monitoring,TDM)代表了个性化医学的早期方法。它帮助临床医生个体化药物治疗,并指导剂量以达到与治疗效果相关的系统药物浓度,或降低与浓度相关的不良反应的风险。TDM 作为医疗保健服务已经进入第五十个年头,这个概念仍在不断发展,新的临床应用领域不断涌现。本文的目的是讨论未来 TDM 服务中有前途的新治疗领域,如何提高对单一药物测量的临床解释,以及最近的技术发展如何为研究和新应用开辟道路。

相似文献

1
Therapeutic drug monitoring for tomorrow.明天的治疗药物监测。
Eur J Clin Pharmacol. 2013 May;69 Suppl 1:25-32. doi: 10.1007/s00228-013-1504-x. Epub 2013 May 3.
2
Biosensing Technologies for Therapeutic Drug Monitoring.用于治疗药物监测的生物传感技术。
Curr Med Chem. 2018;25(34):4354-4377. doi: 10.2174/0929867324666170720101736.
3
Overview of therapeutic drug monitoring of immunosuppressive drugs: Analytical and clinical practices.免疫抑制剂治疗药物监测概述:分析和临床实践。
J Pharm Biomed Anal. 2021 Oct 25;205:114315. doi: 10.1016/j.jpba.2021.114315. Epub 2021 Aug 8.
4
Therapeutic drug monitoring in pregnancy.妊娠期治疗药物监测。
Ther Drug Monit. 2012 Oct;34(5):507-11. doi: 10.1097/FTD.0b013e318261c372.
5
Therapeutic drug monitoring in a developing country: an overview.发展中国家的治疗药物监测:概述
Br J Clin Pharmacol. 1999 Nov;48(5):649-54. doi: 10.1046/j.1365-2125.1999.00088.x.
6
Principles of therapeutic drug monitoring.治疗药物监测的原则。
Handb Exp Pharmacol. 2011;205:77-90. doi: 10.1007/978-3-642-20195-0_3.
7
[Therapeutic monitoring: analytic, pharmacokinetic and clinical aspects].[治疗监测:分析、药代动力学及临床方面]
Acta Clin Belg. 1999;53 Suppl 1:2-12.
8
An introduction to drug testing: the expanding role of mass spectrometry.
Methods Mol Biol. 2012;902:1-13. doi: 10.1007/978-1-61779-934-1_1.
9
Biosensors and nanobiosensors for therapeutic drug and response monitoring.用于治疗药物和反应监测的生物传感器与纳米生物传感器。
Analyst. 2016 Jan 21;141(2):429-49. doi: 10.1039/c5an01861g. Epub 2015 Dec 3.
10
Analytical methods for therapeutic drug monitoring.
Am J Med Technol. 1983 Aug;49(8):551-6.

引用本文的文献

1
Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKI) for optimized outcome in patients with metastatic renal cell carcinoma. The TKI-TDM Trial. Study protocol.酪氨酸激酶抑制剂(TKI)的治疗药物监测(TDM)以优化转移性肾细胞癌患者的治疗效果。TKI-TDM试验。研究方案。
Acta Oncol. 2025 Jun 2;64:729-733. doi: 10.2340/1651-226X.2025.43693.
2
Influence of genetic polymorphisms on pharmacokinetics and treatment response of mycophenolic acid: a scoping review.遗传多态性对霉酚酸药代动力学和治疗反应的影响:范围综述。
Pharmacogenomics. 2024;25(5-6):259-288. doi: 10.1080/14622416.2024.2344430. Epub 2024 May 16.
3

本文引用的文献

1
Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study.106 例接受大型骨科手术后预防静脉血栓栓塞症的患者中达比加群和利伐沙班的测量:一项观察性研究。
J Thromb Thrombolysis. 2013 Feb;35(2):140-6. doi: 10.1007/s11239-012-0803-x.
2
Rational use of aminoglycosides--review and recommendations by the Swedish Reference Group for Antibiotics (SRGA).氨基糖苷类药物的合理使用——瑞典抗生素参考小组(SRGA)的综述与建议
Scand J Infect Dis. 2013 Mar;45(3):161-75. doi: 10.3109/00365548.2012.747694. Epub 2012 Dec 28.
3
Innovative Solid-Phase Extraction Strategies for Improving the Advanced Chromatographic Determination of Drugs in Challenging Biological Samples.
创新固相萃取策略提高复杂生物样本中药物的先进色谱测定。
Molecules. 2024 May 12;29(10):2278. doi: 10.3390/molecules29102278.
4
Revolutionizing Precision Medicine: Exploring Wearable Sensors for Therapeutic Drug Monitoring and Personalized Therapy.**译文**:颠覆精准医学:探索可穿戴传感器在治疗药物监测和个性化治疗中的应用。
Biosensors (Basel). 2023 Jul 12;13(7):726. doi: 10.3390/bios13070726.
5
Solid Phase-Based Microextraction Techniques in Therapeutic Drug Monitoring.治疗药物监测中基于固相的微萃取技术
Pharmaceutics. 2023 Mar 24;15(4):1055. doi: 10.3390/pharmaceutics15041055.
6
Therapeutic drug monitoring practices of anti-infectives: An Asia-wide cross-sectional survey.抗感染药物的治疗药物监测实践:一项全亚洲范围的横断面调查。
Front Pharmacol. 2022 Oct 10;13:992354. doi: 10.3389/fphar.2022.992354. eCollection 2022.
7
Therapeutic Drug Monitoring of Tigecycline in 67 Infected Patients and a Population Pharmacokinetics/Microbiological Evaluation of Study.67例感染患者替加环素的治疗药物监测及一项研究的群体药代动力学/微生物学评价
Front Microbiol. 2021 Jun 16;12:678165. doi: 10.3389/fmicb.2021.678165. eCollection 2021.
8
Towards wearable and implantable continuous drug monitoring: A review.迈向可穿戴和可植入式连续药物监测:综述
J Pharm Anal. 2021 Feb;11(1):1-14. doi: 10.1016/j.jpha.2020.08.001. Epub 2020 Aug 15.
9
Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer.基于帕博利珠单抗的治疗方案中延长给药间隔或延迟给药与晚期非小细胞肺癌生存结局的关系。
Clin Lung Cancer. 2021 May;22(3):e379-e389. doi: 10.1016/j.cllc.2020.05.028. Epub 2020 Jun 5.
10
Pharmacokinetics of methylphenidate and ritalinic acid in plasma correlations with exhaled breath and oral fluid in healthy volunteers.健康志愿者中血浆中哌醋甲酯和利他林酸的药代动力学与呼气和口腔液的相关性。
Eur J Clin Pharmacol. 2020 Feb;76(2):229-237. doi: 10.1007/s00228-019-02787-x. Epub 2019 Nov 30.
Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.
危重症患者β-内酰胺类药代动力学变异性是否需要治疗药物监测?系统评价。
Ann Intensive Care. 2012 Jul 28;2(1):35. doi: 10.1186/2110-5820-2-35.
4
Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin?危重症患者的抗生素持续输注:β-内酰胺类和万古霉素的新圣杯?
Ann Intensive Care. 2012 Jul 2;2(1):22. doi: 10.1186/2110-5820-2-22.
5
Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.连续性肾脏替代治疗的危重症患者的抗生素浓度变异性:一项多中心药代动力学研究。
Crit Care Med. 2012 May;40(5):1523-8. doi: 10.1097/CCM.0b013e318241e553.
6
What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance.危重症患者中新型抗生素治疗失败的原因是什么?了解药代动力学改变和肾脏清除率增加的影响。
Int J Antimicrob Agents. 2012 Jun;39(6):455-7. doi: 10.1016/j.ijantimicag.2012.02.010. Epub 2012 Apr 6.
7
Current applications of high-resolution mass spectrometry in drug metabolism studies.高分辨率质谱在药物代谢研究中的应用现状。
Anal Bioanal Chem. 2012 May;403(5):1221-31. doi: 10.1007/s00216-012-5807-z. Epub 2012 Feb 16.
8
Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations.在某些危重症患者中初始β-内酰胺类药物浓度低于治疗范围:增强的肾脏清除率与低药物谷浓度之间的关系。
Chest. 2012 Jul;142(1):30-39. doi: 10.1378/chest.11-1671.
9
Using pharmacogenetics in real time to guide warfarin initiation: a clinician update.实时应用药物遗传学指导华法林起始治疗:临床医生最新资讯
Circulation. 2011 Dec 6;124(23):2554-9. doi: 10.1161/CIRCULATIONAHA.111.019737.
10
Therapeutic drug monitoring for drugs used in the treatment of substance-related disorders: literature review using a therapeutic drug monitoring appropriateness rating scale.治疗物质相关障碍药物的治疗药物监测:使用治疗药物监测适宜性评分量表进行文献回顾。
Ther Drug Monit. 2011 Oct;33(5):561-72. doi: 10.1097/FTD.0b013e31822fbf7c.